The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer

BACKGROUND: Pancreatic cancer continues to have a 5-year survival of less than 5%. Therefore, more effective therapies are necessary to improve prognosis in this disease. Angiogenesis is required for tumor growth, and subsequently, mediators of angiogenesis are attractive targets for therapy. Vascul...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Dineen, Sean P, Sullivan, Laura A, Beck, Adam W, Miller, Andrew F, Carbon, Juliet G, Mamluk, Roni, Wong, Henry, Brekken, Rolf A
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2008
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2627916/
https://ncbi.nlm.nih.gov/pubmed/19038046
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-8-352
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak